Literature DB >> 34723194

Risk Factors and Referral Rates for Urinary Tract Infection in Pregnant Mothers of Southwest Guatemala.

Michael Miller1, Molly Lamb2, Claudia Rivera2, Saskia Bunge Montes2, Andrea Jimenez-Zambrano2, Antonio Bolanos2, Edwin Asturias2, Stephen Berman2, Margo S Harrison3.   

Abstract

Entities:  

Keywords:  Guatemala; Latin America; Pregnancy; Urinary Tract Infection

Year:  2021        PMID: 34723194      PMCID: PMC8554951     

Source DB:  PubMed          Journal:  J Womens Health Dev        ISSN: 2644-2884


× No keyword cloud information.
Urinary tract infections (UTIs) affect one in four women in low- and middle- income countries and are associated with adverse maternal and neonatal outcomes [1, 2]. In Latin America, the prevalence of UTI is estimated to be 23–31%, yet data in this region is sparse [3]. The objective of this analysis was to understand the prevalence, referral rates, and risk factors associated with UTIs in the Southwest Trifinio region of Guatemala. This study is a secondary analysis of a prospective cohort enrolled in the Madres Sanas community prenatal nursing program in Southwest Guatemala from 2018 to 2020. Study approval was obtained from the Colorado Multiple Institutional Review Board. Women enrolled in the Madres Sanas program who provided at least one dipstick urine sample and had a documented birth were included in the cohort. The study’s primary outcome was presence or absence of UTI as indicated by dipstick (leukocyte esterase count > 15, protein ≥ 30 mg/dL, or a positive result for nitrites) at any point during four antenatal visits. SAS software University Edition version 9.4 was used for analysis (SAS Institute Inc., Cary, North Carolina). From 2018 to 2020, 344 pregnant women were included in this cohort. On average, the population was 24 years old and had 2 prior pregnancies. The majority of the population received some formal (primary or higher) education, were married, had a weekly income ≤ $5 USD, and were not employed by the local agribusiness. Prevalence of UTI among the cohort was 12.8% with an incidence of 60.9 per 1,000 individuals. Rate of referral for positive UTI was 32.1%, and UTI accounted for the greatest number of referrals compared to all other reasons for referral. Rate of repeat positive dipstick was 15.9%, though it was unknown whether this was the result of reinfection or inadequate treatment. No significant differences in bivariate analyses were observed between women with and without diagnosis of antepartum UTI (data not shown). Pregnant mothers with no formal education had a non-significant increased risk of UTI (aRR 1.8; 95% CI: 0.94, 3.32), and mothers working for the local agribusiness had an increased but non-significant risk of UTI (aRR: 2.4; 95% CI: 0.89, 6.18) in a generalized linear regression model (Table 1).
Table 1:

Crude and adjusted risk ratios for education and employment at Banasa and risk of urinary tract infection.

RR95 CIp-valueaRR95 CIp-value
Education Level
No formal education1.8(0.9, 3.4)0.071.8(0.9, 3.3)0.08
Some Education------
Employed
Yes2.4(0.9, 6.5)0.082.3(0.9, 6.2)0.09
No------
Based on our results, we conclude there is a need for prospective research on UTI in this population with confirmatory culture, and observation of treatment practices and pregnancy outcomes associated with UTI diagnosis.
  2 in total

1.  Effect of population-based antenatal screening and treatment of genitourinary tract infections on birth outcomes in Sylhet, Bangladesh (MIST): a cluster-randomised clinical trial.

Authors:  Anne Cc Lee; Luke C Mullany; Mohammad Quaiyum; Dipak K Mitra; Alain Labrique; Parul Christian; Parvez Ahmed; Jamal Uddin; Iftekhar Rafiqullah; Sushil DasGupta; Mahmoodur Rahman; Emilia H Koumans; Salahuddin Ahmed; Samir K Saha; Abdullah H Baqui
Journal:  Lancet Glob Health       Date:  2019-01       Impact factor: 38.927

Review 2.  An introduction to the epidemiology and burden of urinary tract infections.

Authors:  Martha Medina; Edgardo Castillo-Pino
Journal:  Ther Adv Urol       Date:  2019-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.